ONO-4007 is a new synthetic
lipid A derivative with low endotoxic activities. We have examined the
therapeutic effects of
ONO-4007 on rat
hepatocellular carcinoma KDH-8 cells, rat
fibrosarcoma KMT-17 cells and rat mammary
adenocarcinoma SST-2 cells in vivo. Multiple systemic i.v. administration of
ONO-4007 was performed on days 7, 14 and 21 after
tumor implantation of KDH-8 and SST-2 cells, and on days 5, 10 and 15 after
tumor implantation of KMT-17 cells.
ONO-4007 showed significant
therapeutic effects on KDH-8 cells; by the administration of
ONO-4007 (2.5 mg/kg) 70% of rats were cured and by the administration of
ONO-4007 (5 mg/kg) 50% of rats were cured. Furthermore, the
ONO-4007 treatment prolonged the mean survival time of KDH-8-bearing rats. However,
ONO-4007 had no effect on KMT-17 and SST-2 cells, and it had no direct effect on the growth of KDH-8 cells in vivo. Albeit the stimulation with
ONO-4007 induced
mRNA expressions of
interleukin (IL)-1alpha,
IL-6 and
tumor necrosis factor (TNF)-a, those of
IL-2,
IL-4,
IL-10 and
interferon (IFN)-gamma were not induced. Using a bioassay, we found that the production of
TNF-alpha in the
tumor tissues was induced by
ONO-4007 in a dose-dependent manner. KDH-8 cells were sensitive to human natural
TNF-alpha in vitro. However, KMT-17 and SST-2 cells were resistant against
TNF-alpha in vitro. These results suggest that
ONO-4007 is therapeutically useful for the treatment of
TNF-alpha-sensitive
tumors.